

June 29, 2024

To  The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> Floor, Dalal Street Mumbai – 400001  <b>Code: 540222</b>	To  The Listing Department National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051  <b>Code: LAURUSLABS</b>
--	--

**Sub: Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015**

Dear Sirs/Madam,

Further to our intimation dated 19<sup>th</sup> April, 2024, on the inspection conducted by the United States Food & Drug Administration (USFDA) at our API manufacturing facilities Unit-1 and Unit-3, Parawada, Anakapalli (Visakhapatnam), Andhra Pradesh from 15<sup>th</sup> April, 2024 to 19<sup>th</sup> April, 2024, we are pleased to inform you that the Company has received the Establishment Inspection Report (EIR), indicating closure of the inspection.

This is for your information and record.

Yours faithfully,  
**For Laurus Labs Limited**

**G. Venkateswar Reddy**  
**Company Secretary &**  
**Compliance Officer**

**Registered Office**

Laurus Enclave, Plot Office 01, E, Bonangi Village,  
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

**T** +91 891 682 1101, 1102, **E** info@lauruslabs.com  
**F** +91 891 682 1103, **W** lauruslabs.com

CIN : L24239AP2005PLC047518,

**Corporate Office**

2<sup>nd</sup> Floor, SDE Serene Chambers, Road No. 7,  
Banjara Hills, Hyderabad - 500034, Telangana, India.

**T** +91 40 6659 4333, 3980 4333, 2342 0500 / 501,  
**F** +91 40 6659 4320 / 3980 4320